Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2), which is responsible for coronavirus disease (COVID-19), potentially has severe adverse effects, leading to public health crises worldwide. In COVID-19, deficiency of ACE-2 is linked to increased inflammation and cytokine storms via increased angiotensin II levels and decreased ACE-2/Mas receptor axis activity. MiRNAs are small sequences of noncoding RNAs that regulate gene expression by binding to the targeted mRNAs. MiR-200 dysfunction has been linked to the development of ARDS following acute lung injury and has been proposed as a key regulator of ACE2 expression. LncRNA growth arrest-specific transcript 5 (GAS5) has been recently studied for its modulatory effect on the miRNA-200/ACE2 axis.
Objective: The current study aims to investigate the role of lncRNA GAS5, miRNA-200, and ACE2 as new COVID-19 diagnostic markers capable of predicting the severity of SARS-CoV-2 complications.
Methods: A total of 280 subjects were classified into three groups: COVID-19-negative controls (n = 80), and COVID-19 patients (n=200) who required hospitalization were classified into two groups: group (2) moderate cases (n = 112) and group (3) severe cases (n = 88).
Results: The results showed that the serum GAS5 expression was significantly down-expressed in COVID-19 patients; as a consequence, the expression of miR-200 was reported to be overexpressed and its targeted ACE2 was down-regulated. The ROC curve was drawn to examine the diagnostic abilities of GAS5, miR-200, and ACE2, yielding high diagnostic accuracy with high sensitivity and specificity.
Conclusion: lncRNA-GAS5, miRNA-200, and ACE2 panels presented great diagnostic potential as they demonstrated the highest diagnostic accuracy for discriminating moderate COVID-19 and severe COVID-19 cases.
[http://dx.doi.org/10.1002/jmv.27661] [PMID: 35150458]
[http://dx.doi.org/10.1016/j.mgene.2020.100831] [PMID: 33224734]
[http://dx.doi.org/10.1038/s41588-020-00759-x] [PMID: 33432184]
[http://dx.doi.org/10.3389/fphar.2021.684610] [PMID: 34177593]
[http://dx.doi.org/10.2174/22123873MTA2iMTYgx] [PMID: 32338224]
[http://dx.doi.org/10.3390/ijms22136703] [PMID: 34201415]
[http://dx.doi.org/10.1038/celldisc.2017.21] [PMID: 28690868]
[PMID: 35916829]
[http://dx.doi.org/10.3389/fgene.2021.683809] [PMID: 34421993]
[PMID: 30440128]
[http://dx.doi.org/10.2147/CEG.S297428] [PMID: 34079323]
[http://dx.doi.org/10.5114/pjr.2020.98009] [PMID: 32817769]
[http://dx.doi.org/10.1186/s13244-020-00933-z] [PMID: 33226521]
[http://dx.doi.org/10.1038/s41598-021-82970-2] [PMID: 33564039]
[http://dx.doi.org/10.1038/s41590-021-01104-y] [PMID: 35105985]
[http://dx.doi.org/10.1016/j.ajem.2022.01.028] [PMID: 35121478]
[http://dx.doi.org/10.3389/fmed.2021.694029] [PMID: 34513868]
[http://dx.doi.org/10.1111/bph.15082] [PMID: 32333398]
[http://dx.doi.org/10.1016/j.cbi.2022.110276] [PMID: 36414029]
[http://dx.doi.org/10.1111/bph.15154] [PMID: 32497257]
[http://dx.doi.org/10.1186/s12933-018-0771-3] [PMID: 30227878]
[http://dx.doi.org/10.1016/j.pcd.2020.08.018] [PMID: 32912711]
[PMID: 33577038]
[http://dx.doi.org/10.1080/14756366.2021.1995379] [PMID: 34894966]
[http://dx.doi.org/10.1016/j.chest.2019.06.008] [PMID: 31255581]
[http://dx.doi.org/10.1002/jcp.30041] [PMID: 32901940]